Chronic Kidney Disease (CKD) Models
Ace Therapeutics delivers comprehensive preclinical services using validated chronic kidney disease models to support renal drug development. Rodent CKD models recapitulate hallmarks of human disease including fibrosis, inflammation, reduced filtration and uremia. Our multidisciplinary team designs and executes bespoke in vivo studies that inform decision-making at every stage of preclinical research.
CKD encompasses a spectrum of renal dysfunctions, from early-stage glomerular injury to late-stage fibrosis and end-organ failure. Successful therapeutic development demands preclinical models that reflect this heterogeneity. Our team integrates decades of experience in nephrology research with cutting-edge methodologies to deliver models that capture key disease mechanisms, including:
By prioritizing translational relevance, we help clients identify promising candidates while mitigating risks in downstream development.
Ace Therapeutics offers end-to-end chronic kidney disease model selection and study execution. We integrate surgical, dietary and chemical induction approaches, animal welfare oversight, power calculations and standardized endpoints. Dedicated project managers and scientific liaisons guide each study from protocol design through data delivery.
Early-stage CKD models simulate mild-to-moderate renal impairment, ideal for evaluating interventions targeting disease progression. Our protocols incorporate longitudinal biomarkers (e.g., albuminuria, serum creatinine) and histopathological endpoints to detect subtle therapeutic effects.
For programs focused on late-stage CKD, we employ models with established tubulointerstitial fibrosis and impaired renal function. These systems enable robust assessment of anti-fibrotic agents and renoprotective therapies.
Recognizing the interplay between CKD and conditions like hypertension or diabetes, we offer models that replicate multifactorial disease environments. These platforms support mechanistic studies of metabolic-renal crosstalk and combination therapy efficacy.
Ace Therapeutics's CKD model portfolio includes multiple rodent models designed to recapitulate key aspects of human chronic kidney disease. Table 1 summarizes our principal models, species/strain information and key validation endpoints.
| Model Name | Induction Method | Key Validation Endpoints |
| Unilateral ureteral obstruction (UUO) fibrosis | Ligation of left ureter via flank incision | Tubulointerstitial fibrosis by Masson's trichrome, collagen I/III immunostaining; BUN, serum creatinine; ECM deposition |
| Adenine diet-induced injury | 0.50–0.75% adenine in chow for 4 weeks | Renal crystalline deposits and inflammation; BUN/Cr; tubular atrophy; interstitial fibrosis |
| 5/6 nephrectomy (remnant kidney) progression | One kidney removal + 2/3 infarction or pole ablation of contralateral | Progressive albuminuria; glomerulosclerosis score; tubulointerstitial fibrosis; BUN/Cr |
| Spontaneously hypertensive rat (SHR) | Genetic hypertension in bred lines | Arteriolar media hypertrophy; glomerulosclerosis; proteinuria; blood pressure elevation |
Table 1. Principal CKD models with species/strain, induction methods and validation endpoints.
We employ state-of-the-art techniques to characterize disease progression and therapeutic responses:
Robust preclinical validation mitigates translational risk. Our expertise in CKD modeling, advanced analytics and flexible study designs ensures that your therapeutic candidates are evaluated in models most relevant to their mechanism of action. Transparent communication and collaborative problem-solving foster long-term partnerships.
What types of CKD models do you offer
We provide surgical (5/6Nx), dietary (adenine), chemical (cisplatin, streptozotocin) and obstructive (UUO) models to replicate diverse aspects of human CKD.
How do you ensure data quality and reproducibility
All studies follow standardized protocols, power-based animal allocations and blinded endpoint assessments. Data undergo rigorous QA/QC and traceability checks.
Can you adapt models to specific therapeutic targets
Yes. We customize induction methods, dosing regimens and endpoint selections to align with your target biology and mode of action.
What endpoints are available for CKD assessment
Endpoints include renal function markers (creatinine, BUN), histopathology scoring, fibrosis quantification, biomarker profiling and in vivo imaging metrics.
Do you offer study design consultation
Absolutely. Our scientific team collaborates with clients to define objectives, select models and optimize protocols for maximum translational relevance.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics has a group of highly committed and skilled researchers with the objective to provide innovative preclinical contract research solutions to cope with kidney diseases.
We strives to accelerate the development of innovative therapies that address unmet medical needs.